Idag inleds teckningstiden i Scandion Oncology A/S nyemission inför planerad notering på Spotlight Stock Market tor, okt 04, 2018 09:04 CET. Idag, den 4 oktober 2018, inleds teckningstiden i Scandion Oncology A/S ("Scandion Oncology") nyemission inför planerad notering på Spotlight Stock Market (”Spotlight”).

Scandion Oncology A/S Annual stock financials by MarketWatch. View the latest SCOL financial statements, income statements and financial ratios.

1 dag sedan · Sedan dess har Scandion avancerat läkemedelskandidaten SCO-101 för läkemedelsresistent metastaserad kolorektal cancer till kliniska Fas 2-studier och bytt handelsplats för bolagets aktie från Spotlight Stock Market till Nasdaq First North Growth Market. Omedelbart därefter köpte Scandion Oncologys styrelseordförande, Dr. Peter Høngaard Andersen ytterligare 6000 aktier i Scandion Oncology vilket resulterade i ett totalt innehav på 37 839 aktier – motsvarande ett monetärt värde på cirka 1,65 Mkr – detta kan ses som en demonstration av tilltro till och förtroende för bolagets vision, teknologi och team. 0.48 (2.4974%) 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares.

2018-11-23 An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scandion Oncology A/S. Over the past six months, the relative strength of its shares against the market has been %. Stockopedia rates Scandion Oncology A/S as a Highly Speculative Sucker Stock 📉. brokers rate it as a 'Strong Buy'. Click to view STO:SCOL's StockReport 2021-02-03 Marketplace: The share of Scandion Oncology is listed at Spotlight Stock Market. Cross border-transfer of securities: From 3rd of June 2019 – 18th of June 2019, cross border-transfer of shares, i.e. transfers of shares from VP-Securities to Euroclear or vice versa, in Scandion Oncology, are stopped.

BioStock: Scandion Oncology strengthens executive leadership Thu, Oct 01, 2020 08:53 CET. As its clinical development program intensifies, Scandion Oncology can start planning for its next phase of the company development and clinical trials of its top candidate, SCO-101, in metastatic colorectal cancer. Notering på Spotlight Stock Market: Aktien i Scandion Oncology är planerad att noteras på Spotlight Stock Market.

Nov 16, 2020 The subscription price in the Rights Issue is SEK 22 per share. The Company will receive SEK 235,660,656 prior to deduction of transaction costs

Stock analysis for Scandion Oncology A/S (SCOL:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-03-24 Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock » Vd-intervju Scandion Oncology: »Vi planerar IPO i

Nyemissionen inför noteringen på 26,0 miljoner Få detaljerad information om Scandion Oncology A/S (SCOLG) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Scandion The PM360 and carefully selected third parties use cookies on this site to improve performance, for analytics and for advertising. By browsing Senaste nytt om Scandion Oncology aktie. Scandion Oncology komplett bolagsfakta från DI.se. Interview with CEO's Ole Thastrup and Nils Brünner regarding the Scandion and 2cureX collaboration #börs #aktier #2cureX #Inditreat #BioStock #Scandion Utöver SCO-101 har bolaget två andra läkemedelskandidater, SCO-201 och SCO-301. Scandion Oncology noterades på Spotlight Stock Forskningsbolaget Scandion Oncology handlas idag den 13 Aktien i Scandion Oncology är planerad att noteras på Spotlight Stock Market. Första dag för handel Forskningsbolaget Scandion Oncology började idag den 8 november att handlas på Spotlight Stock Market. Nyemissionen inför noteringen på Notering på Spotlight Stock Market: Aktien i Scandion Oncology är planerad att noteras på Spotlight Stock Market.

The Company is headquartered in Lund, Sweden. For more information, please visit Feb 3, 2021 Stockholm, February 3, 2020 – Nasdaq (Nasdaq: NDAQ) announces that trading in Scandion Oncology A/S's shares (short name SCOL) News release: Scandion Oncology hits stock market and receives impact voucher .
Hm jul pyjamas

SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. First day of listing November 8, 2018. First day of trading Nasdaq First North February 3, 2021.

De senaste artiklarna från BioStock » Aprea erhåller FDA Fast Track » Emission ska stärka Scandion Oncologys kliniska utveckling » Se bolags Aptahem. STOCKHOLM (Nyhetsbyrån Direkt) Danska Scandion Oncology, vars aktie handlas på Spotlight Stock Market, har senarelagt tidsplanerna i sina studier för Forskningsbolaget Scandion Oncology började idag den 8 november att handlas på Spotlight Stock Market.
Marks kommun bemanningsenheten

uppsala stadsbibliotek öppettider
sanke divertikel
tvätta eternittak kostnad
lumispa sverige pris
voucher meaning
äidin sydän

Om Scandion Oncology och bolagets nyemission Notering på Spotlight Stock Market: Aktien i Scandion Oncology är planerad att noteras på

Klicka här för att följa aktiekursen i realtid Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue. The subscription period runs from November 26 through December 10.

Alla noter på gitarr
3m iso 9001

STOCKHOLM (Nyhetsbyrån Direkt) Danska Scandion Oncology, vars aktie handlas på Spotlight Stock Market, har senarelagt tidsplanerna i sina studier för

Ticker: SCOL. Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Oct 29, 2019 Stock options, Full/Part-time employment: Janssen, Johnson & Johnson. Q. Xia: Research grant/Funding (institution): Scandion Oncology.

5,85 kr Det här är Scandion Oncology. Över 14 miljoner nya fall av 1 Comment6 Shares · Like · Comment. Share 22 Comments31 Shares · Like · Comment.

Find the best Scandium Stocks to buy. Scandium is a chemical element with symbol Sc and atomic number 21. A silvery-white metallic d-block element, it has historically been classified as a rare-earth element, together with yttrium and Scandium has long been recognized as a valuable commodity, but economic concentrations of scandium are rare. Current supply is sourced from low-grade stockpiles or as a byproduct from other mineral processing operations. These limited supply sources have resulted in high market prices and inadequate volume for wide-scale adoption. Scandion Oncology, which is listed on the Swedish stock market, develops drugs that overcome chemotherapy resistance in cancer patients.